Site Search
Professionals 216 results
Capabilities 55 results
Practice Area
Today’s dynamic commercial real estate market calls for attorneys who bring a broad platform of skills and experience to the table. Our real estate practice offers institutional knowledge across an extensive array of real estate transactions.
Practice Area
Our REIT attorneys are experienced in the planning and implementation of a variety of organizational and real estate ownership structures used for REIT formations and transactions. We understand the complex requirements of asset ownership and character of income that must be met to qualify for pass-through tax treatment under the Internal Revenue Code. Our team has extensive experience with IPOs, private placement of debt, securitization of debt, public/private preferred and common equity offerings, PIPE transactions, recapitalizations, trust preferred securities, asset purchase and dispositions, §1031 exchanges, and mergers and acquisitions. Our experience in capital raising (via public and private securities offerings), securitization, and structured finance transactions is just as deep.
Practice Area
Bankruptcy Litigation & Investigations
Large corporate bankruptcies and companies in financial distress often spawn a complex web of claims by lenders, trustees, debtors, creditors, creditors’ committees, investors, shareholders, and other constituents. Attorneys in Winston & Strawn’s complex commercial litigation group and restructuring and insolvency group—both ranked in Tier 1 by Best Law Firms®—serve as trusted advisors and resolute advocates to protect clients’ business interests and assets in multifaceted Chapter 11 cases and bankruptcy-related disputes.
Experience 70 results
Experience
|April 29, 2025
Stream Realty Completes Ownership Transfer of Houston Center
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Experience
|March 31, 2025
Insights & News 586 results
Article
|June 17, 2025
|1 Min Read
Anatomy of an Acquittal — Delayed Vindication
This article was originally published in Texas Lawbook. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only.
Client Alert
|June 12, 2025
|3 Min Read
Oregon Enacts SB 951, Restricting PE-Backed MSOs in Physician Practice Transactions
On June 9, 2025, Oregon enacted Senate Bill 951 (SB 951), a sweeping new law significantly limiting how management services organizations (MSOs)—including those backed by private-equity firms—may engage with physician practices. The legislation targets traditional “friendly provider” models by restricting ownership and operational control of professional medical entities and voiding restrictive covenants. Investors must now reassess Oregon-based physician practice investments to ensure compliance by 2026 (for new MSOs) and 2029 (for existing ones). It’s noteworthy that this law will coexist with Oregon’s complicated health care transactions notice law, a law that requires a thorough review of certain health care transactions.
Recognitions
|June 12, 2025
|1 Min Read
Winston & Strawn Recognized in The Legal 500 U.S. 2025
Winston & Strawn is recognized as a top-tier firm in five areas and recommended in an additional 45 categories in the 2025 edition of The Legal 500 U.S. In addition, eight lawyers are listed in the Hall of Fame, four lawyers are recognized as Leading Trial Lawyers, 16 partners were ranked as Leading Partners, four associates are ranked as Leading Associates, one partner is ranked as a Leading Lawyer, five lawyers are recognized as Next Generation Partners, and two lawyers are listed as Rising Stars. A total of 186 lawyers are mentioned by name in Legal 500 United States commentary for their standout contribution to respective practices.
Other Results 31 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)
Law Glossary
What Is the Difference Between a Biosimilar and a Generic Drug?
A biosimilar is a biologic product that—as the name implies—is similar to its reference product. Because of a biologic’s complexity, it is not possible to synthesize identical biosimilars that are identical copies of their associated reference products.